Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-2607-2023Class II

DJO Surgical: Altivate Reverse, Humeral Stem, Small Shell, Size 6 x 108mm, REF: 533-06-108

Encore Medical, LP / initiated 2023-08-04 / Open, Classified / root cause: manufacturing process

Encore Medical, LP began a recall of DJO Surgical: Altivate Reverse, Humeral Stem, Small Shell, Size 6 x 108mm, REF: 533-06-108 on . FDA classified it as Class II and gives the reason as "Orthopedic device components were not subjected to final sterilization before shipment, which if implanted may lead to varying degrees of infection, which may require treatment, prolonged monitoring, and may lead to...". As of , the recall status on record is Open, Classified, and MDM tags the root cause as manufacturing process.

Recall record

Recall number
Z-2607-2023
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
Encore Medical, LP
Product
DJO Surgical: Altivate Reverse, Humeral Stem, Small Shell, Size 6 x 108mm, REF: 533-06-108
Product code
KWS Prosthesis, Shoulder, Semi-Constrained, Metal/Polymer Cemented
Reason for recall
Orthopedic device components were not subjected to final sterilization before shipment, which if implanted may lead to varying degrees of infection, which may require treatment, prolonged monitoring, and may lead to revision surgery
Root cause tag
manufacturing process
FDA root cause
Nonconforming Material/Component
Action
On 8/4/23, recall notices were mailed to surgeons and distributors. They were reminded that starting on 7/3/23 they were contacted by the firm, and asked to quarantine affected devices, and that the affected devices had since been retrieved by the firm's sales representatives. Surgeons were asked to take the following actions: 1) We ask that you reach out to your patient[s] who were implanted with affected components as identified above and consider whether it may be appropriate for your patient to be monitored more closely to watch for signs and symptoms of acute or chronic infection. 2) We have also provided a patient letter for you to provide to your patient[s] who was [were] implanted with an affected component[s] should you prefer a written notification to accompany your verbal contact. 3) Please make the hospital where you implanted the components aware of this action, as appropriate by providing a copy of this communication or verbally notifying the hospital. 4) Please review and complete the enclosed Voluntary Recall Response Form. If you have any questions phone the firm at 1(800)456-8696 between the hours of 7:30AM-6:00PM CST, or e-mail [email protected] In addition, distributors were asked to do the following: Provide the notification to any additional organizations or members within your facility or network where devices subject to this voluntary recall may have been transferred.
Quantity in commerce
15
Distribution
US: AL, AZ, CA, CO, FL, IL, IN, KS, KY, LA, MA, MI, MN, MO, NC, NJ, NY, OH, PA, PR, RI, SC, TX, UT, VA, WA. OUS: Sweden, Australia, France, UK, Colombia, Germany
Product codes and lots
UDI-DI/Lot: 00190446259091/923W1411/April 3, 2029

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-2607-2023
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-2603-2023Class IIOngoingVoluntary: Firm initiated
Z-2604-2023Class IIOngoingVoluntary: Firm initiated
Z-2605-2023Class IIOngoingVoluntary: Firm initiated
Z-2606-2023Class IIOngoingVoluntary: Firm initiated
Z-2607-2023Class IIOngoingVoluntary: Firm initiated